A newly formed gene therapy startup is taking gene delivery technology from ReGenX and a $5 million investment from Fidelity Biosciences to develop new treatments for rare diseases, starting with hemophilia. ReGenX and Fidelity Biosciences announced the launch of Dimension Therapeutics at the end of last month and disclosed the $5 million Series A fundraise […]
Ultragenyx is developing a sialic acid replacement therapy for treatment of the rare, progressive neuromuscular disease hereditary inclusion body myopathy that causes muscles to waste away.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
NeuroTherapeutics Pharma Inc., which is developing drugs to combat central nervous system disorders, has closed a $43 million Series B round of funding that will take it through multiple Phase 2 clinical trials. The company is readying its lead compound, NTP-2014, for an Investigational New Drug application with the U.S. Food and Drug Administration. Receiving […]